These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 25851028)

  • 1. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
    Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
    Grazioli L; Morana G; Kirchin MA; Schneider G
    Radiology; 2005 Jul; 236(1):166-77. PubMed ID: 15955857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors.
    Zarghampour M; Fouladi DF; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Khoshpouri P; Shao N; Pan L; Grimm R; Kamel IR
    J Magn Reson Imaging; 2018 Oct; 48(4):1080-1090. PubMed ID: 29630756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Contrast-Enhanced Sonography Versus MRI With a Liver-Specific Contrast Agent for Diagnosis of Hepatocellular Adenoma and Focal Nodular Hyperplasia.
    Bröker MEE; Taimr P; de Vries M; Braun LMM; de Man RA; Ijzermans JNM; Dwarkasing RS
    AJR Am J Roentgenol; 2020 Jan; 214(1):81-89. PubMed ID: 31573852
    [No Abstract]   [Full Text] [Related]  

  • 11. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
    Grazioli L; Morana G; Kirchin MA; Caccia P; Romanini L; Bondioni MP; Procacci C; Chiesa A
    J Magn Reson Imaging; 2003 May; 17(5):593-602. PubMed ID: 12720270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis.
    Alamri TM; Cerny M; Al Shaikh M; Billiard JS; Olivié D; Chagnon M; Tang A
    Abdom Radiol (NY); 2023 Mar; 48(3):874-885. PubMed ID: 36528729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.
    Agarwal S; Fuentes-Orrego JM; Arnason T; Misdraji J; Jhaveri KS; Harisinghani M; Hahn PF
    AJR Am J Roentgenol; 2014 Oct; 203(4):W408-14. PubMed ID: 25055198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis.
    Grazioli L; Bondioni MP; Haradome H; Motosugi U; Tinti R; Frittoli B; Gambarini S; Donato F; Colagrande S
    Radiology; 2012 Feb; 262(2):520-9. PubMed ID: 22282184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatobiliary phase liver MRI versus Contrast-Enhanced Ultrasound after an inconclusive extracellular gadolinium-based contrast-enhanced MRI for the diagnosis of benign hepatocellular tumors.
    Tselikas L; Pigneur F; Roux M; Baranes L; Costentin C; Roche V; Calderaro J; Herin E; Laurent A; Zafrani E; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2017 Mar; 42(3):825-832. PubMed ID: 27704147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium.
    Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS
    AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.